• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New VIVUS Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VVUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VVUS

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for VIVUS in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for VVUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in VIVUS. This rating has held steady since February 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2020Wells Fargo & CompanyLower TargetEqual Weight$10.00 ➝ $1.75Low
(Data available from 12/4/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/6/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/5/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
VIVUS logo
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.37
Low: $0.26
High: $0.47

52 Week Range

Now: N/A

Volume

2,026,800 shs

Average Volume

1,441,313 shs

Market Capitalization

$7.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of VIVUS?

The following Wall Street analysts have issued reports on VIVUS in the last year:
View the latest analyst ratings for VVUS.

What is the current price target for VIVUS?

0 Wall Street analysts have set twelve-month price targets for VIVUS in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for VIVUS in the next year.
View the latest price targets for VVUS.

What is the current consensus analyst rating for VIVUS?

VIVUS currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VVUS.

What other companies compete with VIVUS?

How do I contact VIVUS's investor relations team?

VIVUS's physical mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company's listed phone number is (650) 934-5200 and its investor relations email address is [email protected] The official website for VIVUS is www.vivus.com. Learn More about contacing VIVUS investor relations.